6 results
Primary objective: Safety.Secondary objective: Efficacy.
Therefore, we aim to investigate in a pilot trial the effect of SOM230 on predefined endpoints in patients with moderate to severe GO whom have contraindications for prednisolone therapy or decline from prednisolone therapy for other reasons.
The purpose of this study, is to evaluate the efficacy and safety of pasireotide alone or in combination with cabergoline in patients with Cushing*s disease as measured by the proportion of patients achieving normal UFC at the end of the study…
Primary To evaluate the treatment effect of pasireotide s.c. on plasma glucose levels during GTT at the end of s.c. dose escalation phase.Secondary: Pulse rate, hematocrit, insulin, glucagon, GLP-1 and GIP secretion during GTT at the end of s.c.…
PrimaryAssess the safety profile of pasireotide s.c. during the first 8 weeks of treatment with pasireotide s.c.SecondaryAssess the safety profile of pasireotide s.c.at study completionAssess tumor response as measured by disease control rate (DCR)…
The primary, secondary and exploratory objectives of the study are as follows:Part APrimary:• To evaluate the safety and tolerability of the different GEH200520 Injection mass doses and a fixed dose of GEH200521 (18F) Injection when administered…